189333-46-8

Usage

Uses

Used in Advanced Scientific Research:
9-benzyl-2,4-dioxo-3,9-diazaspiro[5.5]undecane-1,5-dicarbonitrile is used as a research compound for its unique structural properties and potential applications in various scientific fields.
Used in Drug Synthesis:
9-benzyl-2,4-dioxo-3,9-diazaspiro[5.5]undecane-1,5-dicarbonitrile is used as a building block or intermediate in the synthesis of new drugs, due to its complex structure and potential reactivity.
Used in Material Science:
9-benzyl-2,4-dioxo-3,9-diazaspiro[5.5]undecane-1,5-dicarbonitrile is used as a component in the development of new materials, potentially offering unique properties due to its bicyclic structure.

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 1176981-06-8 1'-benzyl-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,4'-piperidine]-2,4,6,8-tetraone 
• 13323-40-5 3-benzyl-9-methyl-3,9-diaza-spiro[5.5]undecane 
• 1001054-49-4 3-benzyl-9-cyclobutyl-3,9-diazaspiro[5.5]undecane 
• 189333-49-1 3-benzyl-3,9-diazaspiro[5.5]undecane 
• 929302-01-2 tert-butyl 9-benzyl-3,9-diazaspiro[5.5]undecane-3-carboxylate 
• 170229-04-6 1-t-Butoxycarbonylpiperidine-4,4-diethanol 
• 160133-32-4 ethyl 2-[1-benzyl-4-(2-ethoxy-2-oxoethyl)-4-piperidyl]acetate 
• 189333-48-0 9-benzyl-3,9-diazaspiro[5.5]undecane-2,4-dione 
• 769901-73-7 2,2'-(1-benzylpiperidine-4,4-diyl)diacetic acid 

Relevant academic research and scientific papers

3,9- DIAZASPIRO[5,5] UNDECANE COMPOUND AS FLT3 AND AXL INHIBITORS

Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Sepcifically, disclosed are a compound represented by fomula (I) and a pharmacologically acceptable salt thereof.

Preparation method of 3-alkyl-3, 9-diazaspiro [5, 5] undecane

The invention relates to a preparation method of 3-alkyl-3, 9-diazaspiro [5, 5] undecane. The preparation method comprises the following steps: a. reacting a compound I with cyanoacetate under the action of ammonia water and a catalyst to obtain a compoun

Polymorphism of novel spiroarylphosphine oxide

The invention relates to a polymorphic substance of a compound (2-((5-chloro-2-((2-methoxyl-4-(9-methyl-3,9-diaza-sprio[5.5]hendecane-3-yl)phenyl)amino)pyrimidine-4-yl)amino)phenyl)dimethyl phosphineoxide (compound I). The invention further relates to a m

Preparation method, intermediate and crystal form of spironolamine arylphosphine oxide

The invention discloses a preparation method and a crystal form of high-purity spironolamine arylphosphine oxide. The invention further discloses a method for preparing a compound shown as a formula (I) and an intermediate compound.

Spiro aryl phosphorus oxide or sulfide

The invention discloses a spiro aryl phosphorus oxide or sulfide as ALK inhibitor, and in particular discloses a compound shown in a formula (I) as an ALK inhibitor or a pharmaceutically acceptable salt thereof.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

Substituted Spiroamine Compounds

Substituted spiroamine compounds corresponding to the formula (I) In which m, n, o, p, Q, r, s, t, R1, R2, R3, R4a, R4b, R5a, R5b, R6a, R6b, R7, R8, R9, R10 and R11 have defined meanings; a process for the preparation of such compounds, pharmaceutical compositions containing such compounds and the use of substituted spiroamines for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin 1 receptor.